# Endless Ark

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/endless-ark

- Industry: Biotechnology
- Headquarters: Shenzhen, China
- Latest round: Seed (Jul 17, 2026)
- Investors on record: 4

## About

Based in Shenzhen, China, and founded in 2026, Shenzhen Jinlenke Technology Co., Ltd., trading as Endless Ark, is an AI-driven longevity biotechnology company developing cross-species anti-aging therapeutics using foundation models, multi-omics data, and experimental validation to discover and advance lifespan-extension drug candidates. In July 2026, Endless Ark raised a Seed+ funding led by Unity Ventures, with participation from Monolith Management, Boyu Capital, Xinglian Capital and other investors.

The company provides AI-powered longevity drug discovery and development solutions, leveraging cross-species biological data, foundation models, target identification, and translational research for anti-aging therapeutics.

The company generates revenue through the development and commercialization of longevity therapeutics, companion animal anti-aging drugs, precision health services, and other related services.

The Seed+ funding raised in July 2026 will primarily be used for pipeline R&D, AI system construction, and team building.

## Funding rounds

- Seed, Jul 17, 2026 — Boyu Capital, Unity Ventures, Monolith Management, Xinglian Capital

## Investors

- Boyu Capital (https://capitalatlas.ai/funds/boyu-capital) — Seed
- Unity Ventures (https://capitalatlas.ai/funds/unity-ventures) — Seed
- Monolith Management (https://capitalatlas.ai/funds/monolith-management) — Seed
- Xinglian Capital (https://capitalatlas.ai/funds/xinglian-capital) — Seed